July 23 (Reuters) - Thermo Fisher on Wednesday

beat Wall Street estimates for second-quarter profit and

revenue, helped by steady demand for its products and services

used for developing therapies.

Shares of the medical equipment maker were up 2.5% in

premarket trading.

The company joins peers such as Danaher ( DHR ) in beating

quarterly profit estimates, citing strong demand from the

industry for tools and services used to make vaccines and

therapies.

Danaher ( DHR ) said on Tuesday it is seeing a robust number of

clinical trials and therapies under development, with steady

demand from its pharmaceutical clients.

On an adjusted basis, Thermo Fisher reported a profit of

$5.36 per share for the quarter ended June 28, beating analysts'

estimate of $5.22 per share, as per data compiled by LSEG.

The company said its business strategy called "practical

process improvement" is helping adjust its supply chains in the

tariff environment and to actively manage its cost base.

Last week, the company said it will buy French drugmaker

Sanofi's New Jersey manufacturing site, "to meet

growing demand from pharma and biotech customers."

The Waltham Massachusetts-based company's quarterly revenue

rose 3% to $10.85 billion, compared to analyst estimates of

$10.68 billion.

Sales at its laboratory products segment, which makes up

more than half of Thermo Fisher's total sales came in at $6

billion, above estimates of $5.79 billion.